Clinical Trial Update: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing different dosing amounts of the drug combination M1774 and ZEN-3694 for recurrent ovarian and endometrial cancers; currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Clear Cell Adenocarcinoma
• Endometrioid Adenocarcinoma of the Endometrium
• Ovarian Cancer
• Ovarian Clear Cell Adenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian High Grade Serous Adenocarcinoma
• Platinum-resistant Ovarian Carcinoma

Drugs mentioned

• M1774
• ZEN-3694

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Status: RECRUITING